Biological activity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action
A novel IgG Fc by computer-aided design enhances heavy-chain heterodimerization in bi- or trispecific antibodies
Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity
Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2
First-in-class trispecific VHH-Fc based antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 and variants
Fc-competent multispecific PDL-1/TIGIT/LAG-3 antibodies potentiate superior anti-tumor T cell response
Abstract LB067: Development of a novel bispecific antibody targeting PD-L1 and CD55 for cancer therapy
Antibody humanization and optimization, Art of safety efficacy and manufacture-ability balance
3541 Investment Blvd. Suite 3,
Hayward, CA 94545 USA
